pioglitazone has been researched along with Urinary Bladder Neoplasms in 84 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To conduct a systematic review of all observational studies on the effect of pioglitazone on the risk of bladder cancer." | 9.01 | A systematic review of observational studies of the association between pioglitazone use and bladder cancer. ( Abrahamowicz, M; Azoulay, L; Platt, RW; Ripamonti, E; Suissa, S, 2019) |
| "We performed a meta-analysis of epidemiological studies evaluating exposure to pioglitazone and the risk for bladder cancer and compared these results to the drug's effects on cardiovascular disease (CVD) and non-alcoholic steatohepatitis (NASH)." | 8.98 | An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. ( Davidson, MB; Pan, D, 2018) |
| "Current evidence about the association between pioglitazone and bladder cancer risk remains conflict." | 8.98 | Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. ( Fu, S; Han, J; Shi, W; Song, Y; Tang, H; Wang, T; Zhai, S, 2018) |
| "Previous epidemiological studies reported inconsistent results regarding the association between pioglitazone use and the risk of bladder cancer (BC)." | 8.95 | Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis . ( Li, Z; Shi, J; Sun, M; Wang, F; Wang, K, 2017) |
| "In preclinical studies, pioglitazone was associated with bladder cancer in male rats (but not in female rats, mice dogs or monkeys)." | 8.93 | Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence. ( Davidson, MB, 2016) |
| "Pioglitazone is widely used for glycemic control in patients with type 2 diabetes mellitus, but evidence regarding the association between pioglitazone and bladder cancer risk is confusing." | 8.90 | Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. ( He, S; Tang, YH; Wang, D; Yang, X; Zhang, Y; Zhao, G, 2014) |
| "Electronic databases were queried to identify controlled studies of pioglitazone that measured the risk of bladder cancer." | 8.89 | Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. ( Al-Mallah, MH; Ferwana, M; Firwana, B; Hasan, R; Kim, S; Montori, VM; Murad, MH, 2013) |
| "This article reviews human observations on pioglitazone and bladder cancer risk." | 8.88 | Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? ( Tseng, CH, 2012) |
| "Emerging studies suggest a possible increased risk of bladder cancer with pioglitazone therapy." | 8.88 | Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. ( Lu, Y; Shen, Z; Xu, C; Zhong, S; Zhu, Z, 2012) |
| " Food and Drug Administration and the European Medicines Agency have recently informed the public of a potential impact of pioglitazone (Actos) use on bladder cancer incidence." | 8.88 | Association between pioglitazone and urothelial bladder cancer. ( Barbalat, Y; Dombrovskiy, VY; Weiss, RE, 2012) |
| "National regulators in Australia and the United Kingdom issued safety advisories on the association between pioglitazone use and bladder cancer in July 2011." | 8.12 | Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study. ( Dormuth, CR; Kemp-Casey, A; Mintzes, B; Morrow, RL; Roughead, EE; Souverein, PC, 2022) |
| "Pioglitazone use in Asian-Indians is not associated with an increased bladder cancer risk." | 8.12 | Bladder cancer with pioglitazone: A case-control study. ( Bhadada, SK; Bhansali, A; Hiteshi, P; Khalkho, P; Kumar, N; Malhotra, B; Malhotra, S; Malik, R; Rajput, R; Rastogi, A; Shafiq, N, 2022) |
| "This paper thoroughly explores both in vitro and in vivo (animal models and humans) studies that investigated the possible association of pioglitazone with bladder cancer." | 8.12 | Pioglitazone, Bladder Cancer, and the Presumption of Innocence. ( Papaetis, GS, 2022) |
| "In 2011, France and Germany banned pioglitazone due to a concomitant risk for bladder cancer." | 7.91 | Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis. ( Bhushan, S; Prakash, J; Ray, RS; Singh, GN, 2019) |
| "The aim of the study was to empirically demonstrate the effect of varying study designs when evaluating the safety of pioglitazone in treating bladder cancer." | 7.91 | Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. ( Buse, JB; Garry, EM; Gokhale, M; Lund, JL; Nielsen, ME; Pate, V; Stürmer, T, 2019) |
| "To compare bladder cancer incidence between patients initiating pioglitazone treatment and patients initiating treatment with dipeptidyl-peptidase-4 inhibitors [DPP-4s] or sulfonylureas." | 7.88 | Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. ( Buse, JB; Garry, EM; Lund, JL; Pate, V; Stürmer, T, 2018) |
| "It has been debated for several years as to whether the antidiabetic drug pioglitazone increases the risk for bladder cancer." | 7.85 | Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes. ( Liu, Z; Qu, H; Ruan, X; Wang, Y; Yang, G; Zhang, R; Zheng, H; Zheng, Y, 2017) |
| "To determine whether pioglitazone compared with other antidiabetic drugs is associated with an increased risk of bladder cancer in people with type 2 diabetes." | 7.83 | Pioglitazone use and risk of bladder cancer: population based cohort study. ( Azoulay, L; Filion, KB; Platt, RW; Tuccori, M; Yin, H; Yu, OH, 2016) |
| " To evaluate the association between pioglitazone use and bladder cancer risk in patients with type 2 diabetes." | 7.83 | Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. ( Bahmanyar, S; Christopher, S; Dolin, P; Heintjes, EM; Hoti, F; Kool-Houweling, L; Korhonen, P; Linder, M; Majak, M; Strongman, H; Williams, R, 2016) |
| "The evidence on the association between pioglitazone use and bladder cancer is contradictory, with many studies subject to allocation bias." | 7.81 | Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. ( Badrick, E; Bell, S; Bowker, SL; Buchan, IE; Colhoun, HM; de Keyser, CE; Hartikainen, SA; Hofman, A; Johnson, JA; Keskimäki, I; Levin, D; MacDonald, TM; Marra, C; McKeigue, PM; Minhas-Sandhu, JK; Pukkala, E; Renehan, AG; Ruiter, R; Stricker, BH; Sund, R; Tuomilehto, J; Uitterlinden, AG; Wild, SH; Zafari, Z, 2015) |
| "Among 193,099 persons in the bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2." | 7.81 | Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. ( Bilker, W; Ehrlich, SF; Ferrara, A; Habel, LA; Hedderson, MM; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, CP; Strom, BL; Van Den Eeden, SK; Vaughn, DJ, 2015) |
| "The observed association between pioglitazone and bladder cancer could be causal or because of bias in the design of prior studies." | 7.80 | Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. ( Bilker, WB; Ferrara, A; Habel, L; Hedderson, M; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, C; Strom, BL; Vaughn, DJ, 2014) |
| "Although studies have shown an association between pioglitazone and bladder cancer, the associated factors have not been identified." | 7.80 | The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease. ( Hsiao, PJ; Lee, MY; Lin, KD; Shin, SJ; Yang, YH, 2014) |
| "This study aimed to identify the risk association between pioglitazone exposure and bladder cancer." | 7.80 | Pioglitazone use and the risk of bladder cancer. ( Ho, SC; Kuo, HW; Tiao, MM; Yang, CY, 2014) |
| "Prospective studies suggested an association between pioglitazone (Actos) use and the development of bladder cancer." | 7.80 | Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use. ( Gray, I; Hemal, A; Peyton, C; Romero, V; Terlecki, R, 2014) |
| "It has not yet been determined whether chronic exposure to relatively low doses of pioglitazone increases risk of bladder cancer." | 7.80 | Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. ( Chang, JS; Cho, JH; Jin, SM; Jung, CH; Jung, I; Kang, SM; Kim, JH; Lee, BW; Park, CY; Song, SO; Suh, S, 2014) |
| "Evidence has emerged that pioglitazone may increase the risk of bladder cancer, but the association has not been confirmed." | 7.79 | Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study. ( Gau, CS; Hsiao, FY; Hsieh, PH; Huang, WF; Tsai, YW, 2013) |
| "To examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus." | 7.79 | Pioglitazone and bladder cancer: a propensity score matched cohort study. ( MacDonald, TM; Mackenzie, IS; Wei, L, 2013) |
| "We retrospectively examined the frequency of bladder cancer in Japanese patients with type 2 diabetes in relation to use of pioglitazone." | 7.79 | Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. ( Fujikawa, J; Fujimoto, K; Hamamoto, Y; Honjo, S; Ikeda, H; Kawasaki, Y; Koshiyama, H; Matsuoka, A; Mori, K; Tatsuoka, H; Wada, Y, 2013) |
| "The association between pioglitazone and bladder cancer has not been investigated in Asians." | 7.78 | Pioglitazone and bladder cancer: a population-based study of Taiwanese. ( Tseng, CH, 2012) |
| "To determine if the use of pioglitazone is associated with an increased risk of incident bladder cancer in people with type 2 diabetes." | 7.78 | The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. ( Assayag, J; Azoulay, L; Filion, KB; Majdan, A; Pollak, MN; Suissa, S; Yin, H, 2012) |
| "Previous studies have suggested an increased risk of bladder cancer with pioglitazone exposure." | 7.78 | Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. ( Alla, F; Allemand, H; Fagot, JP; Neumann, A; Ricordeau, P; Weill, A, 2012) |
| "To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications." | 7.77 | Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. ( Marchesini, G; Motola, D; Piccinni, C; Poluzzi, E, 2011) |
| "Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy." | 7.77 | Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. ( Bilker, WB; Ferrara, A; Hedderson, M; Lewis, JD; Nessel, L; Peng, T; Quesenberry, CP; Selby, J; Strom, BL; Vaughn, DJ, 2011) |
| "Since then, the risk of bladder cancer associated with pioglitazone use has been a serious concern." | 6.49 | Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? ( Faillie, JL; Hillaire-Buys, D; Montastruc, JL; Petit, P, 2013) |
| "Type 2 diabetes mellitus and bladder cancer were diagnosed using the International Statistical Classification of Diseases and Related Health Problems, 10th Revision code." | 5.43 | Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. ( Choe, EY; Han, E; Jang, SY; Kang, ES; Kim, G; Lee, YH; Nam, CM, 2016) |
| "To conduct a systematic review of all observational studies on the effect of pioglitazone on the risk of bladder cancer." | 5.01 | A systematic review of observational studies of the association between pioglitazone use and bladder cancer. ( Abrahamowicz, M; Azoulay, L; Platt, RW; Ripamonti, E; Suissa, S, 2019) |
| "Current evidence about the association between pioglitazone and bladder cancer risk remains conflict." | 4.98 | Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. ( Fu, S; Han, J; Shi, W; Song, Y; Tang, H; Wang, T; Zhai, S, 2018) |
| "We performed a meta-analysis of epidemiological studies evaluating exposure to pioglitazone and the risk for bladder cancer and compared these results to the drug's effects on cardiovascular disease (CVD) and non-alcoholic steatohepatitis (NASH)." | 4.98 | An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. ( Davidson, MB; Pan, D, 2018) |
| "Previous epidemiological studies reported inconsistent results regarding the association between pioglitazone use and the risk of bladder cancer (BC)." | 4.95 | Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis . ( Li, Z; Shi, J; Sun, M; Wang, F; Wang, K, 2017) |
| "In preclinical studies, pioglitazone was associated with bladder cancer in male rats (but not in female rats, mice dogs or monkeys)." | 4.93 | Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence. ( Davidson, MB, 2016) |
| "Pioglitazone is widely used for glycemic control in patients with type 2 diabetes mellitus, but evidence regarding the association between pioglitazone and bladder cancer risk is confusing." | 4.90 | Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. ( He, S; Tang, YH; Wang, D; Yang, X; Zhang, Y; Zhao, G, 2014) |
| " The use of pioglitazone has been associated with an increased risk of bladder cancer, edema, heart failure, weight gain, and distal bone fractures in postmenopausal women." | 4.89 | [Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus]. ( de Pablos-Velasco, PL; Valerón, PF, 2013) |
| "Electronic databases were queried to identify controlled studies of pioglitazone that measured the risk of bladder cancer." | 4.89 | Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. ( Al-Mallah, MH; Ferwana, M; Firwana, B; Hasan, R; Kim, S; Montori, VM; Murad, MH, 2013) |
| "This article reviews human observations on pioglitazone and bladder cancer risk." | 4.88 | Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? ( Tseng, CH, 2012) |
| " Food and Drug Administration and the European Medicines Agency have recently informed the public of a potential impact of pioglitazone (Actos) use on bladder cancer incidence." | 4.88 | Association between pioglitazone and urothelial bladder cancer. ( Barbalat, Y; Dombrovskiy, VY; Weiss, RE, 2012) |
| "Emerging studies suggest a possible increased risk of bladder cancer with pioglitazone therapy." | 4.88 | Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. ( Lu, Y; Shen, Z; Xu, C; Zhong, S; Zhu, Z, 2012) |
| "The limited evidence available supports the hypothesis that thiazolidinediones, particularly pioglitazone, are associated with an increased risk of bladder cancer among adults with type 2 diabetes." | 4.88 | Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. ( Bowker, SL; Colmers, IN; Johnson, JA; Majumdar, SR, 2012) |
| "This paper thoroughly explores both in vitro and in vivo (animal models and humans) studies that investigated the possible association of pioglitazone with bladder cancer." | 4.12 | Pioglitazone, Bladder Cancer, and the Presumption of Innocence. ( Papaetis, GS, 2022) |
| "National regulators in Australia and the United Kingdom issued safety advisories on the association between pioglitazone use and bladder cancer in July 2011." | 4.12 | Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study. ( Dormuth, CR; Kemp-Casey, A; Mintzes, B; Morrow, RL; Roughead, EE; Souverein, PC, 2022) |
| "Pioglitazone use in Asian-Indians is not associated with an increased bladder cancer risk." | 4.12 | Bladder cancer with pioglitazone: A case-control study. ( Bhadada, SK; Bhansali, A; Hiteshi, P; Khalkho, P; Kumar, N; Malhotra, B; Malhotra, S; Malik, R; Rajput, R; Rastogi, A; Shafiq, N, 2022) |
| "The aim of the study was to empirically demonstrate the effect of varying study designs when evaluating the safety of pioglitazone in treating bladder cancer." | 3.91 | Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. ( Buse, JB; Garry, EM; Gokhale, M; Lund, JL; Nielsen, ME; Pate, V; Stürmer, T, 2019) |
| "In 2011, France and Germany banned pioglitazone due to a concomitant risk for bladder cancer." | 3.91 | Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis. ( Bhushan, S; Prakash, J; Ray, RS; Singh, GN, 2019) |
| "To compare bladder cancer incidence between patients initiating pioglitazone treatment and patients initiating treatment with dipeptidyl-peptidase-4 inhibitors [DPP-4s] or sulfonylureas." | 3.88 | Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. ( Buse, JB; Garry, EM; Lund, JL; Pate, V; Stürmer, T, 2018) |
| "Pioglitazone was suspended for manufacture and sale by the Indian drug regulator in June 2013 due to its association with urinary bladder carcinoma, which was revoked within a short period (July 2013)." | 3.85 | Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study. ( Adhikari, A; Ambwani, S; Badyal, DK; Bairy, KL; Bhandare, B; Chakrabarti, A; Chandrashekar, K; Das, N; Dhamija, P; Dhasmana, DC; Goyal, A; Goyal, C; Gupta, YK; Jayanthi, CR; Kakkar, AK; Kaur, I; Kaushal, S; Kumar, R; Mazumdar, G; Munshi, R; Rehman, SU; Sarangi, SC; Sehgal, VK; Singh, H; Singh, J; Stephy, DJ; Thangaraju, P, 2017) |
| "It has been debated for several years as to whether the antidiabetic drug pioglitazone increases the risk for bladder cancer." | 3.85 | Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes. ( Liu, Z; Qu, H; Ruan, X; Wang, Y; Yang, G; Zhang, R; Zheng, H; Zheng, Y, 2017) |
| " To evaluate the association between pioglitazone use and bladder cancer risk in patients with type 2 diabetes." | 3.83 | Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. ( Bahmanyar, S; Christopher, S; Dolin, P; Heintjes, EM; Hoti, F; Kool-Houweling, L; Korhonen, P; Linder, M; Majak, M; Strongman, H; Williams, R, 2016) |
| "To determine whether pioglitazone compared with other antidiabetic drugs is associated with an increased risk of bladder cancer in people with type 2 diabetes." | 3.83 | Pioglitazone use and risk of bladder cancer: population based cohort study. ( Azoulay, L; Filion, KB; Platt, RW; Tuccori, M; Yin, H; Yu, OH, 2016) |
| "The evidence on the association between pioglitazone use and bladder cancer is contradictory, with many studies subject to allocation bias." | 3.81 | Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. ( Badrick, E; Bell, S; Bowker, SL; Buchan, IE; Colhoun, HM; de Keyser, CE; Hartikainen, SA; Hofman, A; Johnson, JA; Keskimäki, I; Levin, D; MacDonald, TM; Marra, C; McKeigue, PM; Minhas-Sandhu, JK; Pukkala, E; Renehan, AG; Ruiter, R; Stricker, BH; Sund, R; Tuomilehto, J; Uitterlinden, AG; Wild, SH; Zafari, Z, 2015) |
| "Among 193,099 persons in the bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2." | 3.81 | Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. ( Bilker, W; Ehrlich, SF; Ferrara, A; Habel, LA; Hedderson, MM; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, CP; Strom, BL; Van Den Eeden, SK; Vaughn, DJ, 2015) |
| "It has not yet been determined whether chronic exposure to relatively low doses of pioglitazone increases risk of bladder cancer." | 3.80 | Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. ( Chang, JS; Cho, JH; Jin, SM; Jung, CH; Jung, I; Kang, SM; Kim, JH; Lee, BW; Park, CY; Song, SO; Suh, S, 2014) |
| "This study aimed to identify the risk association between pioglitazone exposure and bladder cancer." | 3.80 | Pioglitazone use and the risk of bladder cancer. ( Ho, SC; Kuo, HW; Tiao, MM; Yang, CY, 2014) |
| "Although studies have shown an association between pioglitazone and bladder cancer, the associated factors have not been identified." | 3.80 | The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease. ( Hsiao, PJ; Lee, MY; Lin, KD; Shin, SJ; Yang, YH, 2014) |
| "The observed association between pioglitazone and bladder cancer could be causal or because of bias in the design of prior studies." | 3.80 | Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. ( Bilker, WB; Ferrara, A; Habel, L; Hedderson, M; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, C; Strom, BL; Vaughn, DJ, 2014) |
| "Prospective studies suggested an association between pioglitazone (Actos) use and the development of bladder cancer." | 3.80 | Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use. ( Gray, I; Hemal, A; Peyton, C; Romero, V; Terlecki, R, 2014) |
| "Compared with insulin, pioglitazone was associated with a significant reduction in the risk of MI and stroke requiring hospitalization, and a significant reduction in the risk of other selected cancers." | 3.79 | Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. ( Bron, M; Fusco, G; Joseph, G; Liang, H; Manne, S; Perez, A; Vallarino, C; Yu, S, 2013) |
| "To examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus." | 3.79 | Pioglitazone and bladder cancer: a propensity score matched cohort study. ( MacDonald, TM; Mackenzie, IS; Wei, L, 2013) |
| "Evidence has emerged that pioglitazone may increase the risk of bladder cancer, but the association has not been confirmed." | 3.79 | Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study. ( Gau, CS; Hsiao, FY; Hsieh, PH; Huang, WF; Tsai, YW, 2013) |
| "We retrospectively examined the frequency of bladder cancer in Japanese patients with type 2 diabetes in relation to use of pioglitazone." | 3.79 | Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. ( Fujikawa, J; Fujimoto, K; Hamamoto, Y; Honjo, S; Ikeda, H; Kawasaki, Y; Koshiyama, H; Matsuoka, A; Mori, K; Tatsuoka, H; Wada, Y, 2013) |
| "The use of pioglitazone, a thiazolidinedione (TZD), may increase the risk of bladder cancer in patients with type 2 diabetes." | 3.78 | Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. ( Bilker, WB; Glanz, K; Haynes, K; Lewis, JD; Mamtani, R; Strom, BL; Vaughn, DJ, 2012) |
| "The association between pioglitazone and bladder cancer has not been investigated in Asians." | 3.78 | Pioglitazone and bladder cancer: a population-based study of Taiwanese. ( Tseng, CH, 2012) |
| "Previous studies have suggested an increased risk of bladder cancer with pioglitazone exposure." | 3.78 | Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. ( Alla, F; Allemand, H; Fagot, JP; Neumann, A; Ricordeau, P; Weill, A, 2012) |
| "To determine if the use of pioglitazone is associated with an increased risk of incident bladder cancer in people with type 2 diabetes." | 3.78 | The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. ( Assayag, J; Azoulay, L; Filion, KB; Majdan, A; Pollak, MN; Suissa, S; Yin, H, 2012) |
| "Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy." | 3.77 | Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. ( Bilker, WB; Ferrara, A; Hedderson, M; Lewis, JD; Nessel, L; Peng, T; Quesenberry, CP; Selby, J; Strom, BL; Vaughn, DJ, 2011) |
| "To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications." | 3.77 | Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. ( Marchesini, G; Motola, D; Piccinni, C; Poluzzi, E, 2011) |
| "Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow-up; however, these imbalances should be interpreted with caution because of the limitations of the observational study design." | 2.82 | Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. ( Erdmann, E; Harding, S; Lam, H; Perez, A, 2016) |
| "The double-blind period bladder cancer imbalance did not persist in follow-up." | 2.79 | Observational follow-up of the PROactive study: a 6-year update. ( Erdmann, E; Perez, A; Song, E; Spanheimer, R; van Troostenburg de Bruyn, AR, 2014) |
| "Since then, the risk of bladder cancer associated with pioglitazone use has been a serious concern." | 2.49 | Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? ( Faillie, JL; Hillaire-Buys, D; Montastruc, JL; Petit, P, 2013) |
| "Type 2 diabetes mellitus and bladder cancer were diagnosed using the International Statistical Classification of Diseases and Related Health Problems, 10th Revision code." | 1.43 | Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. ( Choe, EY; Han, E; Jang, SY; Kang, ES; Kim, G; Lee, YH; Nam, CM, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (3.57) | 29.6817 |
| 2010's | 76 (90.48) | 24.3611 |
| 2020's | 5 (5.95) | 2.80 |
| Authors | Studies |
|---|---|
| Papaetis, GS | 1 |
| Kemp-Casey, A | 1 |
| Mintzes, B | 1 |
| Morrow, RL | 1 |
| Dormuth, CR | 1 |
| Souverein, PC | 1 |
| Roughead, EE | 1 |
| Malhotra, B | 1 |
| Hiteshi, P | 1 |
| Khalkho, P | 1 |
| Malik, R | 1 |
| Bhadada, SK | 1 |
| Bhansali, A | 1 |
| Shafiq, N | 1 |
| Malhotra, S | 1 |
| Kumar, N | 1 |
| Rajput, R | 1 |
| Rastogi, A | 1 |
| Bhushan, S | 1 |
| Ray, RS | 1 |
| Prakash, J | 1 |
| Singh, GN | 1 |
| Jeong, HE | 1 |
| Cho, SI | 1 |
| Oh, IS | 1 |
| Baek, YH | 1 |
| Shin, JY | 1 |
| Ripamonti, E | 2 |
| Azoulay, L | 4 |
| Abrahamowicz, M | 2 |
| Platt, RW | 3 |
| Suissa, S | 3 |
| Atlı Şekeroğlu, Z | 1 |
| Şekeroğlu, V | 1 |
| Kontaş Yedier, S | 1 |
| İlkun, E | 1 |
| Liou, LS | 1 |
| Aschenbrenner, DS | 1 |
| Garry, EM | 2 |
| Buse, JB | 2 |
| Lund, JL | 2 |
| Pate, V | 2 |
| Stürmer, T | 2 |
| Li, R | 1 |
| Metcalfe, MJ | 1 |
| Ferguson, JE | 1 |
| Mokkapati, S | 1 |
| Nogueras González, GM | 1 |
| Dinney, CP | 1 |
| Navai, N | 1 |
| McConkey, DJ | 1 |
| Sahai, SK | 1 |
| Kamat, AM | 1 |
| Davidson, MB | 2 |
| Pan, D | 1 |
| Qu, H | 1 |
| Zheng, Y | 1 |
| Wang, Y | 1 |
| Zhang, R | 1 |
| Ruan, X | 1 |
| Yang, G | 1 |
| Liu, Z | 1 |
| Zheng, H | 1 |
| Goyal, A | 1 |
| Singh, H | 1 |
| Sehgal, VK | 1 |
| Jayanthi, CR | 1 |
| Munshi, R | 1 |
| Bairy, KL | 1 |
| Kumar, R | 1 |
| Kaushal, S | 1 |
| Kakkar, AK | 1 |
| Ambwani, S | 1 |
| Goyal, C | 1 |
| Mazumdar, G | 1 |
| Adhikari, A | 1 |
| Das, N | 1 |
| Stephy, DJ | 1 |
| Thangaraju, P | 1 |
| Dhasmana, DC | 1 |
| Rehman, SU | 1 |
| Chakrabarti, A | 1 |
| Bhandare, B | 1 |
| Badyal, DK | 1 |
| Kaur, I | 1 |
| Chandrashekar, K | 1 |
| Singh, J | 1 |
| Dhamija, P | 1 |
| Sarangi, SC | 1 |
| Gupta, YK | 1 |
| Tang, H | 1 |
| Shi, W | 1 |
| Fu, S | 1 |
| Wang, T | 1 |
| Zhai, S | 1 |
| Song, Y | 1 |
| Han, J | 1 |
| Griebling, TL | 1 |
| Gokhale, M | 1 |
| Nielsen, ME | 1 |
| Ryder, REJ | 1 |
| DeFronzo, RA | 1 |
| Gomella, LG | 1 |
| de Vries, F | 1 |
| Zeegers, M | 1 |
| Goossens, ME | 1 |
| Unnikrishnan, R | 2 |
| Sundramoorthy, C | 1 |
| Deshpande, N | 1 |
| Sarvothaman, R | 1 |
| Sahay, RK | 1 |
| Mehtalia, S | 1 |
| Venkatraman, JV | 1 |
| Mohan, V | 2 |
| Hsiao, FY | 1 |
| Hsieh, PH | 1 |
| Huang, WF | 1 |
| Tsai, YW | 1 |
| Gau, CS | 1 |
| Erdmann, E | 2 |
| Song, E | 1 |
| Spanheimer, R | 1 |
| van Troostenburg de Bruyn, AR | 1 |
| Perez, A | 3 |
| Faillie, JL | 4 |
| Petit, P | 2 |
| Montastruc, JL | 2 |
| Hillaire-Buys, D | 4 |
| Vallarino, C | 1 |
| Fusco, G | 1 |
| Liang, H | 1 |
| Bron, M | 1 |
| Manne, S | 1 |
| Joseph, G | 1 |
| Yu, S | 1 |
| He, S | 1 |
| Tang, YH | 1 |
| Zhao, G | 1 |
| Yang, X | 1 |
| Wang, D | 1 |
| Zhang, Y | 1 |
| Lee, MY | 1 |
| Hsiao, PJ | 1 |
| Yang, YH | 1 |
| Lin, KD | 1 |
| Shin, SJ | 1 |
| Valerón, PF | 1 |
| de Pablos-Velasco, PL | 1 |
| Kuo, HW | 1 |
| Tiao, MM | 1 |
| Ho, SC | 1 |
| Yang, CY | 1 |
| Romero, V | 1 |
| Peyton, C | 1 |
| Gray, I | 1 |
| Hemal, A | 1 |
| Terlecki, R | 1 |
| Jin, SM | 1 |
| Song, SO | 1 |
| Jung, CH | 1 |
| Chang, JS | 1 |
| Suh, S | 1 |
| Kang, SM | 1 |
| Jung, I | 1 |
| Park, CY | 1 |
| Kim, JH | 1 |
| Cho, JH | 1 |
| Lee, BW | 1 |
| Tseng, CH | 3 |
| Lewis, JD | 4 |
| Habel, L | 1 |
| Quesenberry, C | 1 |
| Mamtani, R | 3 |
| Peng, T | 3 |
| Bilker, WB | 3 |
| Hedderson, M | 2 |
| Nessel, L | 3 |
| Vaughn, DJ | 4 |
| Strom, BL | 4 |
| Ferrara, A | 3 |
| Mello, MM | 1 |
| Cohen, IG | 1 |
| Kernan, WN | 1 |
| Viscoli, CM | 1 |
| Varughese, MC | 1 |
| Lee, EJ | 1 |
| Marcy, TR | 1 |
| Ryder, RE | 1 |
| Levin, D | 1 |
| Bell, S | 1 |
| Sund, R | 1 |
| Hartikainen, SA | 1 |
| Tuomilehto, J | 1 |
| Pukkala, E | 1 |
| Keskimäki, I | 1 |
| Badrick, E | 1 |
| Renehan, AG | 1 |
| Buchan, IE | 1 |
| Bowker, SL | 2 |
| Minhas-Sandhu, JK | 1 |
| Zafari, Z | 1 |
| Marra, C | 1 |
| Johnson, JA | 3 |
| Stricker, BH | 1 |
| Uitterlinden, AG | 1 |
| Hofman, A | 1 |
| Ruiter, R | 1 |
| de Keyser, CE | 1 |
| MacDonald, TM | 2 |
| Wild, SH | 1 |
| McKeigue, PM | 1 |
| Colhoun, HM | 1 |
| Habel, LA | 1 |
| Quesenberry, CP | 2 |
| Hedderson, MM | 1 |
| Ehrlich, SF | 1 |
| Bilker, W | 1 |
| Van Den Eeden, SK | 1 |
| Warren, H | 1 |
| Raison, N | 1 |
| Dasgupta, P | 1 |
| Harding, S | 1 |
| Lam, H | 1 |
| Han, E | 1 |
| Jang, SY | 1 |
| Kim, G | 1 |
| Lee, YH | 1 |
| Choe, EY | 1 |
| Nam, CM | 1 |
| Kang, ES | 1 |
| Chedgy, EC | 1 |
| Black, PC | 1 |
| Tuccori, M | 1 |
| Filion, KB | 2 |
| Yin, H | 2 |
| Yu, OH | 1 |
| Kado, T | 1 |
| Usui, I | 1 |
| Tobe, K | 1 |
| Winnenburg, R | 1 |
| Shah, NH | 1 |
| Korhonen, P | 1 |
| Heintjes, EM | 1 |
| Williams, R | 1 |
| Hoti, F | 1 |
| Christopher, S | 1 |
| Majak, M | 1 |
| Kool-Houweling, L | 1 |
| Strongman, H | 1 |
| Linder, M | 1 |
| Dolin, P | 1 |
| Bahmanyar, S | 1 |
| Li, Z | 1 |
| Sun, M | 1 |
| Wang, F | 1 |
| Shi, J | 1 |
| Wang, K | 1 |
| Usman, MS | 1 |
| Rizwan, T | 1 |
| Ahmed, F | 1 |
| Hampp, C | 1 |
| Pippins, J | 1 |
| Sato, K | 1 |
| Awasaki, Y | 1 |
| Kandori, H | 1 |
| Tanakamaru, ZY | 1 |
| Nagai, H | 1 |
| Baron, D | 1 |
| Yamamoto, M | 1 |
| Selby, J | 1 |
| Piccinni, C | 1 |
| Motola, D | 1 |
| Marchesini, G | 1 |
| Poluzzi, E | 1 |
| Stephenson, J | 1 |
| Goldstein, MR | 2 |
| Mascitelli, L | 1 |
| Nicolau Ramis, J | 1 |
| Masmiquel Comas, L | 1 |
| Neumann, A | 1 |
| Weill, A | 1 |
| Ricordeau, P | 1 |
| Fagot, JP | 1 |
| Alla, F | 1 |
| Allemand, H | 1 |
| Wei, L | 1 |
| Mackenzie, IS | 1 |
| Barbalat, Y | 1 |
| Dombrovskiy, VY | 1 |
| Weiss, RE | 1 |
| Assayag, J | 1 |
| Majdan, A | 1 |
| Pollak, MN | 1 |
| Zhu, Z | 1 |
| Shen, Z | 1 |
| Lu, Y | 1 |
| Zhong, S | 1 |
| Xu, C | 1 |
| Bedi, S | 1 |
| Sahay, BK | 1 |
| Joshpi, S | 1 |
| Misra, A | 1 |
| Panikar, V | 1 |
| Kalra, S | 1 |
| Voelker, R | 1 |
| Colmers, IN | 2 |
| Majumdar, SR | 1 |
| Kermode-Scott, B | 1 |
| Haynes, K | 1 |
| Glanz, K | 1 |
| Kawamori, R | 1 |
| Fujimoto, K | 1 |
| Hamamoto, Y | 1 |
| Honjo, S | 1 |
| Kawasaki, Y | 1 |
| Mori, K | 1 |
| Tatsuoka, H | 1 |
| Matsuoka, A | 1 |
| Wada, Y | 1 |
| Ikeda, H | 1 |
| Fujikawa, J | 1 |
| Koshiyama, H | 1 |
| Cagiltay, E | 1 |
| Tuncel, T | 1 |
| Yönem, A | 1 |
| Ozdemir, G | 1 |
| Noon, AP | 1 |
| Catto, JW | 1 |
| Ferwana, M | 1 |
| Firwana, B | 1 |
| Hasan, R | 1 |
| Al-Mallah, MH | 1 |
| Kim, S | 1 |
| Montori, VM | 1 |
| Murad, MH | 1 |
| Achanzar, WE | 1 |
| Moyer, CF | 1 |
| Marthaler, LT | 1 |
| Gullo, R | 1 |
| Chen, SJ | 1 |
| French, MH | 1 |
| Watson, LM | 1 |
| Rhodes, JW | 1 |
| Kozlosky, JC | 1 |
| White, MR | 1 |
| Foster, WR | 1 |
| Burgun, JJ | 1 |
| Car, BD | 1 |
| Cosma, GN | 1 |
| Dominick, MA | 1 |
| Nakashiro, KI | 1 |
| Hayashi, Y | 1 |
| Kita, A | 1 |
| Tamatani, T | 1 |
| Chlenski, A | 1 |
| Usuda, N | 1 |
| Hattori, K | 1 |
| Reddy, JK | 1 |
| Oyasu, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Participation Trends in Bladder Cancer Clinical Trials - Exploring Engagement Dynamics Among Individuals Impacted by Bladder Cancer[NCT06009510] | 500 participants (Anticipated) | Observational | 2024-09-30 | Not yet recruiting | |||
| Cohort Study of Pioglitazone and Bladder Cancer in Patients With Diabetes[NCT01637935] | 193,099 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications.[NCT02678676] | 3,599 participants (Actual) | Observational [Patient Registry] | 2004-11-30 | Completed | |||
| The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial[NCT02491333] | Phase 3 | 342 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Incident bladder cancers were identified from January 1, 1997 to December 31, 2012. (NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | events per 100,000 person years (Number) |
|---|---|
| Pioglitazone Exposed Group | 89.8 |
| Pioglitazone Unexposed Group | 75.9 |
(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | events per 100,000 person years (Number) | ||
|---|---|---|---|
| 1 - 14000 mg | 14001 - 40000 mg | >40000 mg | |
| Pioglitazone Exposed Group | 69.1 | 96.9 | 101.4 |
| Pioglitazone Unexposed Group | NA | NA | NA |
(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | events per 100,000 person years (Number) | ||
|---|---|---|---|
| Less than 1.5 years | 1.5 - 4.0 years | More than 4 years | |
| Pioglitazone Exposed Group | 67.5 | 88.4 | 113.7 |
| Pioglitazone Unexposed Group | NA | NA | NA |
(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | events per 100,000 person years (Number) | ||
|---|---|---|---|
| Less than 4.5 years | 4.5 -8.5 years | More than 8.0 years | |
| Pioglitazone Exposed Group | 68.2 | 111.6 | 125.8 |
| Pioglitazone Unexposed Group | NA | NA | NA |
(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| PUNLMP | In situ | Local | Regional | Distant | Undetermined | |
| Pioglitazone Exposed Group | 1 | 50 | 40 | 4 | 2 | 3 |
| Pioglitazone Unexposed Group | 1 | 49 | 38 | 6 | 3 | 3 |
Percentage of participants with incidences of at least 1 malignancy was reported. All malignancies included adrenal, biliary, bladder, brain, breast, cervix, colon/rectal, gastric, hematological, hepatic, lung, mesothelioma, metastases, oesophageal, oropharyngeal, ovarian/uterine, pancreas, prostate, renal, skin and others. (NCT02678676)
Timeframe: Up to Year 10
| Intervention | percentage of participants (Number) |
|---|---|
| Pioglitazone | 12.9 |
| Placebo | 13.2 |
The composite macro-vascular event or death included all-cause mortality, non-fatal myocardial infarction, cardiac intervention, stroke, major leg amputation (above the ankle), bypass surgery or revascularization in the leg. The percentage of participants in the observational study population having first occurrence of macro-vascular event or death during the 10-year observational study period was analyzed. The data were analyzed using the Cox regression with respect to time to the first occurrence of macro-vascular event or death. (NCT02678676)
Timeframe: Up to Year 10
| Intervention | percentage of participants (Number) |
|---|---|
| Pioglitazone | 58 |
| Placebo | 60.3 |
19 reviews available for pioglitazone and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis.
Topics: Cardiovascular Diseases; Cohort Studies; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Dise | 2018 |
Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Odds Ratio; Pioglitazone; Randomized Control | 2018 |
A systematic review of observational studies of the association between pioglitazone use and bladder cancer.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Incidence; | 2019 |
Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?
Topics: Animals; Europe; Humans; Pharmacoepidemiology; Pioglitazone; Risk Assessment; Thiazolidinediones; Un | 2013 |
Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Pioglitazone; Risk | 2014 |
[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
Topics: Contraindications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Comb | 2013 |
A review on thiazolidinediones and bladder cancer in human studies.
Topics: Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2014 |
Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit.
Topics: Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Disease Models, Animal; Endpoint Determin | 2015 |
Examples of how the pharmaceutical industries distort the evidence of drug safety: the case of pioglitazone and the bladder cancer issue.
Topics: Animals; Drug Industry; Humans; Hypoglycemic Agents; Pharmacoepidemiology; Pioglitazone; Scientific | 2016 |
Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence.
Topics: Diabetes Mellitus, Type 2; Drug Industry; Female; Humans; Hypoglycemic Agents; Male; Pioglitazone; R | 2016 |
Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis
.
Topics: Diabetes Mellitus; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Linear Models; Mul | 2017 |
Pioglitazone and bladder cancer: FDA's assessment.
Topics: Humans; Hypoglycemic Agents; Pioglitazone; Randomized Controlled Trials as Topic; United States; Uni | 2017 |
Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
Topics: Bias; Comorbidity; Data Interpretation, Statistical; Diabetes Complications; Epidemiologic Research | 2012 |
Association between pioglitazone and urothelial bladder cancer.
Topics: Clinical Trials as Topic; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinediones; Urinary Bla | 2012 |
Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Pio | 2012 |
Pioglitazone--where do we stand in India?
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Rela | 2012 |
Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.
Topics: Adult; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Humans; Incidence; Pioglitazone; Rand | 2012 |
Bladder cancer in 2012: Challenging current paradigms.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Cystectomy; Humans; Pioglitazone; Rand | 2013 |
Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
Topics: Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglyce | 2013 |
2 trials available for pioglitazone and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Observational follow-up of the PROactive study: a 6-year update.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi | 2014 |
Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi | 2016 |
63 other studies available for pioglitazone and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Pioglitazone, Bladder Cancer, and the Presumption of Innocence.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Thiazolidine | 2022 |
Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study.
Topics: Aged; Australia; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Interrupted Time Se | 2022 |
Bladder cancer with pioglitazone: A case-control study.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Female; Hematuria; Humans; Hypoglycemic Agents; Mal | 2022 |
Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Female; Global Health; Humans; Hypoglyce | 2019 |
Prescribing trend of pioglitazone after safety warning release in Korea.
Topics: Diabetes Mellitus, Type 2; Drug Utilization; Female; Humans; Hypoglycemic Agents; Interrupted Time S | 2019 |
Pioglitazone and bladder cancer: improving research methods.
Topics: Humans; Hypoglycemic Agents; Pioglitazone; Research Design; Thiazolidinediones; Urinary Bladder Neop | 2020 |
Increased DNA strand breaks and neoplastic transformation in human bladder cells treated with pioglitazone.
Topics: Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Diabetes Mellitus, Type 2; DNA; DN | 2021 |
Updated Review Confirms Potential Risk of Bladder Cancer with Pioglitazone.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Thiazolidinediones; Urin | 2017 |
Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Aging; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV I | 2018 |
Effects of thiazolidinedione in patients with active bladder cancer.
Topics: Aged; Carcinoma, Transitional Cell; Cystectomy; Diabetes Mellitus; Disease-Free Survival; Female; Hu | 2018 |
Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Observational Studies as Topic; Pioglitazone; Randomized Controll | 2017 |
Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study.
Topics: Adult; Aged; Carcinoma; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; India; Male; | 2017 |
Re: Comparative Safety of Pioglitazone versus Clinically Meaningful Treatment Alternatives Concerning the Risk of Bladder Cancer in Older US Adults with Type 2 Diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Urin | 2019 |
Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
Topics: Aged; Aged, 80 and over; Comparative Effectiveness Research; Diabetes Complications; Diabetes Mellit | 2019 |
Pioglitazone: inexpensive; very effective at reducing HbA
Topics: Humans; Hypoglycemic Agents; Pioglitazone; Risk; Thiazolidinediones; Urinary Bladder Neoplasms | 2019 |
Actos, slings, finasteride, and the vaccine compensation solution.
Topics: Finasteride; Humans; Liability, Legal; Male; Patient Rights; Pioglitazone; Prostatic Neoplasms; Risk | 2013 |
Pioglitazone and bladder cancer: two studies, same database, two answers.
Topics: Data Interpretation, Statistical; Databases, Factual; Epidemiologic Research Design; Humans; Hypogly | 2013 |
Eight cases of bladder cancer in pioglitazone users from India.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; India; Male; Middle Age | 2012 |
Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidenc | 2013 |
Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.
Topics: Aged; Aged, 80 and over; Cohort Studies; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Insul | 2013 |
The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
Topics: Adult; Aged; Asian People; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycem | 2014 |
Pioglitazone use and the risk of bladder cancer.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Logistic Models; | 2014 |
Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use.
Topics: Aged; Cystectomy; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Pioglitazone; Retros | 2014 |
Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study.
Topics: Aged; Asian People; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; | 2014 |
Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; California; Cohort Studies; Confounding Factors, Epidemiologic; Diab | 2014 |
Clinical trials and the right to remain silent.
Topics: Access to Information; Biomedical Research; Humans; Hypoglycemic Agents; Pioglitazone; Randomized Co | 2014 |
Litigation seeking access to data from ongoing clinical trials: a threat to clinical research.
Topics: Access to Information; Biomedical Research; Connecticut; Diabetes Mellitus, Type 2; Humans; Hypoglyc | 2014 |
The impact of pioglitazone on bladder cancer and cardiovascular events.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Risk; U | 2014 |
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
Topics: Aged; British Columbia; Diabetes Mellitus, Type 2; Female; Finland; Humans; Hypoglycemic Agents; Inc | 2015 |
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
Topics: Adult; Aged, 80 and over; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Female; H | 2015 |
Pioglitazone and bladder cancer.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinediones; Urinary Bl | 2016 |
Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyp | 2016 |
Pioglitazone: No Longer a Worry for Bladder Cancer?
Topics: Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2016 |
Pioglitazone use and risk of bladder cancer: population based cohort study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; General Practice; Humans; Hypoglycemic Agents; Ma | 2016 |
[Pioglitazone and the risk of bladder cancer].
Topics: Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinedi | 2016 |
Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature.
Topics: Animals; Computational Biology; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemi | 2016 |
Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
Topics: Aged; Datasets as Topic; Diabetes Mellitus, Type 2; Female; Finland; Humans; Hypoglycemic Agents; Ma | 2016 |
A word of caution regarding pioglitazone.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pakistan; Patient Safety; Pioglitazone; Urin | 2017 |
Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats.
Topics: Ammonium Chloride; Animals; Citrates; Diet; Hydrogen-Ion Concentration; Hypoglycemic Agents; Lasers; | 2011 |
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Longitudinal Studies; M | 2011 |
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Female; Humans; Hypoglycemic Agent | 2011 |
Diabetes drug may be associated with increase in risk of bladder cancer.
Topics: Contraindications; Diabetes Mellitus; Drug Labeling; Humans; Hypoglycemic Agents; Pioglitazone; Risk | 2011 |
Pioglitazone for diabetes prevention.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolid | 2011 |
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; | 2012 |
Pioglitazone and bladder cancer: a population-based study of Taiwanese.
Topics: Asian People; Female; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazolidinediones; Urinary B | 2012 |
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
Topics: Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Follow | 2012 |
Pioglitazone and bladder cancer: a propensity score matched cohort study.
Topics: Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; M | 2013 |
Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Oxazoles; Pioglitazone; PPAR alpha; | 2012 |
Pioglitazone and the risk of bladder cancer.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazolidinedion | 2012 |
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.
Topics: Administration, Oral; Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Re | 2012 |
Pioglitazone and bladder cancer: the pros and cons.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Rela | 2012 |
The cage in search of a bird.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Piogl | 2012 |
Diabetes drug is linked with bladder cancer risk.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Labeling; Humans; Hypoglycemic Agents; M | 2012 |
Meta-analysis confirms raised risk of bladder cancer from pioglitazone.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic | 2012 |
Pioglitazone: European approval maintained despite the acknowledged risks.
Topics: Diabetes Mellitus, Type 2; France; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Thiazolidinedion | 2012 |
Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Topics: Aged; Cohort Studies; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Dose-Response R | 2012 |
Balancing the risks and benefits for pioglitazone in type 2 diabetes.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Pio | 2012 |
[Biguanide, pioglitazone and alpha-glucosidase inhibitors].
Topics: Acidosis, Lactic; Biguanides; Body Weight; Chemical and Drug Induced Liver Injury; Digestive System; | 2012 |
Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Piog | 2013 |
Pioglitazone causing urinary bladder cancer? While waiting for the result of the debate, suggestions for physicians.
Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Incidence; Male; Pioglitazone; Prognosis; Ri | 2013 |
PROactive study.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rats; Thiazolidinedio | 2006 |
Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
Topics: Acids; Animals; Cell Proliferation; Diet; Epidermal Growth Factor; Immunohistochemistry; Male; Perox | 2007 |
Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells.
Topics: Aged; Blotting, Western; Cell Division; Cell Line; Chromans; Dose-Response Relationship, Drug; Human | 2001 |